FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
What happened
FDA reviewed the website https://www.24hrdoc.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The product labels pictured on the site show the name "24HrDoc," which suggests 24HrDoc is the compounder of those drugs when it is not. The site also states "Same ingredients as: Ozempic and Wegovy" and "Same ingredients as: Mounjaro and Zepbound," which imply the compounded products were FDA-approved or evaluated for safety and effectiveness when they were not.
What FDA found
The pictured labels carry the 24HrDoc name, which tells buyers 24HrDoc made the drug when it did not.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR 201.1(h)(2)Claiming the products have the same ingredients as Ozempic and Wegovy suggests FDA approval that compounded drugs do not have.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Claiming the products have the same ingredients as Mounjaro and Zepbound suggests FDA approval that compounded drugs do not have.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Sending misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, send the Office of Compounding Quality and Compliance a written response describing the steps taken to fix the violations and prevent them from recurring. FDA specifically asks the company to identify who makes the compounded products, supply sample labeling, and address or remove the misleading website claims.
Who should pay attention
- telehealth platforms that sell compounded semaglutide and tirzepatide
- compounding pharmacies whose products are marketed on third-party websites
- marketing and compliance staff who write prescription drug website copy
This is a summary. Read the original letter on fda.gov.